The systematic review and meta-analysis of 48 trials involving 94,245 individuals show little or no effect of GLP-1 RA treatment on the risk for obesity-related cancers.

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...

What if the race to get thin was quietly putting health at risk? That question is becoming harder to ignore as glucagon‑like ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists and fenofibrate medications significantly reduced the risk for developing diabetic ...

Shares of Structure Therapeutics GPCR skyrocketed 102.5% after the company reported positive top-line data from the ACCESS ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...

In the realm of innovative health solutions, the HonXi SMGT-GLP-1 Nano Microneedle Patch stands out as a revolutionary approach to managing weight and controlling blood sugar levels. As the prevalence ...